Autologous Muscle Derived Stem Cells Transplantation in Urine Incontinency

The investigators will be assessed the 12-month safety and potential efficacy of autologous muscle derived cells as therapy for stress urinary incontinence. A total of 10 women in whom stress urinary incontinence had not improved underwent intra-sphincter injection of low doses 30×106 of autologous muscle derived cells, which will be derived from biopsies of their deltoid muscle. Assessments will be made at 1, 3, 6 and 12 months after cell injection. Changes in stress urinary incontinence severity were evaluated by pad test, diary of incontinence episodes and quality of life surveys.

Inclusion criteria

• Female
• Stress Urinary Incontinence symptoms
• Urodynamic stress incontinence confirmed with multichannel urodynamic testing
• positive cough stress test
• urgency score < stress score
• Patient's age between 40 - 65 years
• Desire to surgical correction of stress urinary incontinence or inadequate response to conservative treatment of SUI

Exclusion criteria

• Post-void residual volume >100cc
• Detrusor overactivity on preoperative multichannel urodynamic testing
• History of previous synthetic, biologic or fascial sub-urethral sling or any other surgery on external genitalia, bladder neck, bladder or urethra
• Desires future childbearing
• Chronic inguinal or vulvar abscess or history of Hidradenitis Suppurative
• History of bleeding diathesis or current anti-coagulation therapy
• Inguinal lymphadenopathy or inguinal/vulvar mass
• Current genitourinary fistula or urethral diverticulum
• Current sever cystocele or rectocele
• Active urinary infection
• Non-treated urge incontinency or any significant voiding dysfunction
• Neuromuscular disorders
• Uncontrolled Diabetes
• Reversible cause of incontinence (i.e. drug effect)
• Contraindications for surgery